ストックスクリーナーアプリを入手
0.7301
7.59%
-0.0601
前日終値:
$0.7901
開ける：
$0.77
24時間の取引高:
921.36K
Relative Volume:
0.09
時価総額：
$32.92M
収益：
$500.00K
当期純損益:
$-19.45M
株価収益率:
-0.3863
EPS:
-1.89
ネットキャッシュフロー:
$-18.22M
1週間 パフォーマンス:
-8.74%
1か月 パフォーマンス:
-49.99%
6か月 パフォーマンス:
-25.48%
1年 パフォーマンス:
-46.32%
1日の値動き範囲:
$0.71
$0.78
1週間の範囲:
$0.71
$0.8199
52週間の値動き範囲:
$0.37
$3.65
Imunon Inc Stock (IMNN) Company Profile
IMNN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
IMNN
Imunon Inc
|
0.73 | 32.92M | 500.00K | -19.45M | -18.22M | -1.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.78 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
537.09 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.01 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
541.62 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
241.70 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Imunon Inc (IMNN) 最新ニュース
IMNN Presents Promising Phase 2 OVATION 2 Study Results at ESMO Congress | IMNN Stock News - GuruFocus
IMUNON Presents Positive Phase 2 Translational Data of IMNN-001 - GuruFocus
IMUNON reports promising ovarian cancer therapy data at ESMO - Investing.com
IMUNON Presents Positive Phase 2 Translational Data of - GlobeNewswire
Breakthrough in Ovarian Cancer Treatment: New Drug Amplifies Immune Response by 62-fold, Phase 3 Trial Begins - Stock Titan
IMUNON reports durability data for COVID-19 vaccine alternative By Investing.com - Investing.com India
IMUNON reports durability data for COVID-19 vaccine alternative - Investing.com Australia
IMNN Showcases Positive Phase 1 Results for DNA Plasmid Vaccine - GuruFocus
IMUNON Announces PlaCCine® DNA Vaccine Technology Abstract Selected for Oral Presentation at 10th International Conference on Vaccines Research & Development™ - The Manila Times
IMUNON Announces PlaCCine® DNA Vaccine Technology Abstract Selected for Oral Presentation at 10th International Conference on Vaccines Research & Development™ | IMNN Stock News - GuruFocus
IMUNON Reports Six-Month Durability and Manufacturing Benefits of PlaCCine® DNA Vaccine Technology Over mRNA Vaccines, Seeks Strategic Partnership - Nasdaq
IMUNON Announces PlaCCine® DNA Vaccine Technology Abstract - GlobeNewswire
IMUNON at ASCO 2025: Changing the micro-tumour environment in advanced ovarian cancer - pharmaphorum
Imunon Inc. appoints new CFO following termination - Investing.com Australia
Imunon Inc. appoints new CFO following termination By Investing.com - Investing.com South Africa
Imunon Appoints Kimberly Graper as Interim CFO - TipRanks
ImunonTerminates CFO David Gaiero's Service Agreement - MarketScreener
Why Imunon, Inc. (IMNN) Surged Last Week - MSN
Imunon regains Nasdaq compliance with bid price By Investing.com - Investing.com South Africa
Imunon Regains Nasdaq Compliance with Bid Price - TipRanks
Imunon regains Nasdaq compliance with bid price - Investing.com
Imunon (NASDAQ:IMNN) Raised to Sell at Wall Street Zen - Defense World
Top Companies in the NASDAQ by Kalkine Leading Market Performers Today - Kalkine Media
Equities Analysts Offer Predictions for Imunon Q2 Earnings - Defense World
IMUNON to Present at the Zacks SCR Life Sciences Virtual Investor Forum on June 12th - GlobeNewswire
Phase 3 DNA Immunotherapy Developer IMUNON Opens Live Q&A with Investors Next Week - Stock Titan
ASCO25: Imunon shares positive results from trial of IMNN-001 for ovarian cancer - Yahoo Finance
IMUNON Announces Data Presented at ASCO Reinforces - GlobeNewswire
Imunon announces data from Phase 2 OVATION 2 study on IMNN-001 - TipRanks
IMUNON Announces Data Presented at ASCO Reinforces Unprecedented - GuruFocus
IMNN: Promising Phase 2 Results in Ovarian Cancer Treatment | IMNN Stock News - GuruFocus
IMUNON Announces Data Presented at ASCO Reinforces Unprecedented Overall Survival in Ovarian Cancer Phase 2 Study - Yahoo Finance
Imunon CEO says company ‘has never been stronger’ - TipRanks
IMNN Advances Cancer Treatment with Promising Phase 2 Results | IMNN Stock News - GuruFocus
IMUNON CEO RECAPS A YEAR OF CLINICAL ACHIEVEMENT AND SOLID FUNDA - GuruFocus
IMUNON CEO RECAPS A YEAR OF CLINICAL ACHIEVEMENT AND SOLID FUNDAMENTALS | IMNN Stock News - GuruFocus
IMUNON CEO RECAPS A YEAR OF CLINICAL ACHIEVEMENT AND SOLID FUNDAMENTALS - The Manila Times
Breakthrough Ovarian Cancer Drug Extends Patient Survival by 13 Months in Phase 2 Trial, ASCO Data Shows - Stock Titan
Should You Buy, Sell, or Hold Shopify Stock in June 2025? - The Globe and Mail
IMUNON launches up to $9.75M securities offering - MSN
Imunon Inc. Faces Nasdaq Delisting Over Compliance Issues By Investing.com - Investing.com Canada
Imunon (IMNN) Announces Plans to Offer 22.03 Million Shares | IM - GuruFocus
Imunon Faces Nasdaq Delisting Due to Non-Compliance - TipRanks
Imunon Inc. Faces Nasdaq Delisting Over Compliance Issues - Investing.com
Public market insider selling at TerraVest Industries (TVK) - The Globe and Mail
Imunon, Inc. (IMNN) Raises $3.25M in Private Placement, Eyes $6.5M More - Yahoo Finance
Imunon Inc (IMNN) 財務データ
収益
当期純利益
現金流量
EPS
Imunon Inc (IMNN) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Lindborg Stacy | President and CEO |
Aug 15 '24 |
Buy |
0.98 |
25,000 |
24,500 |
264,166 |
| Tardugno Michael H | Executive Chairman of Board |
Aug 15 '24 |
Buy |
1.03 |
25,000 |
25,750 |
353,346 |
0.84%
0.47%
大文字化:
|
ボリューム (24 時間):